tirzepatide vs. semaglutide for weight loss and key differences, results (2026) Tirzepatide vs Semaglutide: 2025 NEJM

The growing use and increased prevalence of GLP-1 treatments have led to the recurring practical concern among clinicians: Can breath testing results still be trusted for these patients

Semaglutide, the active ingredient in Ozempic and Wegovy, is labeled to a maximum of 2 mg weekly as Ozempic, while the 2.4 mg weekly dose belongs to Wegovy for weight managementthough most people find their personal optimal dose somewhere lower

Tirzepatide (the active ingredient in Mounjaro/Zepbound) is a dual GLP-1 + GIP agonist, a more potent mechanism

Imaging studies show structural and functional CNS alterations, highlighting CNS dysfunction as a key pain driver